Literature DB >> 1571850

Long-lasting dermatological lesions after tiludronate therapy.

C Roux1, V Listrat, B Villette, M Lessana-Leibowitch, D Ethgen, C Pelissier, M Dougados, B Amor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1571850     DOI： 10.1007/bf00301637

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


× No keyword cloud information.
  8 in total

1.  Prevention of postmenopausal bone loss by tiludronate.

Authors:  J Y Reginster; M P Lecart; R Deroisy; N Sarlet; D Denis; D Ethgen; J Collette; P Franchimont
Journal:  Lancet       Date:  1989 Dec 23-30       Impact factor: 79.321

2.  [How to diagnose a cutaneous complication of a drug. Application to vascular purpura].

Authors:  J C Guillaume; J C Roujeau; J Chevrant-Breton; J Revuz; P Souteyrand; E Albengres; B Begaud; C Benichou; G Danan; J C Evreux
Journal:  Ann Dermatol Venereol       Date:  1987       Impact factor: 0.777

3.  Severe reaction to diphosphonate: implications for treatment of Paget's disease.

Authors:  A T Elliott; T Murray; R M Mackie; J A Hunter
Journal:  BMJ       Date:  1988-09-03

4.  Adverse cutaneous reaction to technetium Tc 99m methylene diphosphonate.

Authors:  M R Collins; W D James; O G Rodman
Journal:  Arch Dermatol       Date:  1988-02

5.  Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases.

Authors:  C A Mautalen; C A Casco; D Gonzalez; G R Ghiringhelli; C Massironi; G A Fromm; L Plantalech
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-17

6.  Severe systemic reaction to diphosphonate bone imaging agents: skin testing to predict allergic response and a safe alternative agent.

Authors:  A Ramos-Gabatin; J A Orzel; T R Maloney; J E Murnane; R D Borchert
Journal:  J Nucl Med       Date:  1986-09       Impact factor: 10.057

Review 7.  Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism.

Authors:  H Fleisch
Journal:  Recent Results Cancer Res       Date:  1989

8.  Determination of (4-chlorophenyl)thiomethylene bisphosphonic acid, a new bisphosphonate, in biological fluids by high-performance liquid chromatography.

Authors:  J P Fels; J Guyonnet; Y Berger; W Cautreels
Journal:  J Chromatogr       Date:  1988-08-19
  8 in total
  4 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 2.  Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases.

Authors:  C J Rosen; C R Kessenich
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 3.  Comparative tolerability of drug therapies for hypercalcaemia of malignancy.

Authors:  N Zojer; A V Keck; M Pecherstorfer
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 4.  A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis.

Authors:  J P Devogelaer
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.